1[1]Stass H, Dalhoff A, Kubitza D. Bay 12～8093: Study on the food the effect after oral administration of 200mg SD to healthy volunteers. ECCMID, 1997, Lausanne: Poster P386. 被引量：1
2[2]Stass H. Pharmacokinetics an elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother,1999, 43(Suppl B) 83～90. 被引量：1
3[3]Stass H. Moxifloxacin～ review of clinical pharmacokinetics. Metabolism and Excretion. 6th New Quinolones Symposium 1999, Denver. poster. 被引量：1
4[4]Stass H, Kubitza D. Study to evaluate the interaction between BAY 1208039 and iron ECC, 1998, Hambury: poster. 被引量：1
5[5]Baz MN, Jannetti W, Villanueva C, et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Todays Ther Trends, 1999, 17(2): 330～319. 被引量：1
6[6]Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther, 1999, 21(10): 1644～1677. 被引量：1
7[7]Chodosh S, Edabate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med,2000, 94(1): 18～27. 被引量：1
8[8]Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbation of chronic bronchitis. J Antimicrob Chemother, 1999, 44(4):501～513. 被引量：1
9[9]Patel T, Pear J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400mg once daily in the treatment of patients with community～acquired pneumonia. Respir Med, 2000,94(2):97～105. 被引量：1
10[10]Hoffken G, Meyeer HP, Sprenger K, et al. Efficacy and safety of moxifloxacin vs clarithromycin for the treatment of community～acquired pneumonia. J Antimicrob Chermother, 1999, 44(Suppl A): 127. 被引量：1
